Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Long Lasting Microvascular Tone Alteration in Rat Offspring Exposed In Utero to Maternal Hyperglycaemia.

Vessières E, Dib A, Bourreau J, Lelièvre E, Custaud MA, Lelièvre-Pégorier M, Loufrani L, Henrion D, Fassot C.

PLoS One. 2016 Jan 12;11(1):e0146830. doi: 10.1371/journal.pone.0146830. eCollection 2016.

2.

Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactions.

Obinata H, Gutkind S, Stitham J, Okuno T, Yokomizo T, Hwa J, Hla T.

J Lipid Res. 2014 Dec;55(12):2665-75. doi: 10.1194/jlr.P054163. Epub 2014 Oct 7.

3.

High throughput mutagenesis for identification of residues regulating human prostacyclin (hIP) receptor expression and function.

Bill A, Rosethorne EM, Kent TC, Fawcett L, Burchell L, van Diepen MT, Marelli A, Batalov S, Miraglia L, Orth AP, Renaud NA, Charlton SJ, Gosling M, Gaither LA, Groot-Kormelink PJ.

PLoS One. 2014 Jun 2;9(6):e97973. doi: 10.1371/journal.pone.0097973. eCollection 2014.

4.

Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF β-Smad signal pathway.

Chen Y, Yang S, Yao W, Zhu H, Xu X, Meng G, Zhang W.

PLoS One. 2014 May 22;9(5):e98483. doi: 10.1371/journal.pone.0098483. eCollection 2014.

5.

Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Tao YX, Conn PM.

Endocr Rev. 2014 Aug;35(4):602-47. doi: 10.1210/er.2013-1121. Epub 2014 Mar 24. Review.

6.

Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists.

Ganesh T, Jiang J, Shashidharamurthy R, Dingledine R.

ACS Med Chem Lett. 2013 Jul 11;4(7):616-621.

7.

Human thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysis.

Gleim S, Stitham J, Tang WH, Li H, Douville K, Chelikani P, Rade JJ, Martin KA, Hwa J.

PLoS One. 2013 Jun 28;8(6):e67314. doi: 10.1371/journal.pone.0067314. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/83ddfba7-3c48-4c96-8cd1-0f0b5f69a5d1.

8.

Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics.

Duarte JD, Hanson RL, Machado RF.

Future Cardiol. 2013 May;9(3):335-49. doi: 10.2217/fca.13.6. Review.

9.

New insights into structural determinants for prostanoid thromboxane A2 receptor- and prostacyclin receptor-G protein coupling.

Chakraborty R, Pydi SP, Gleim S, Bhullar RP, Hwa J, Dakshinamurti S, Chelikani P.

Mol Cell Biol. 2013 Jan;33(2):184-93. doi: 10.1128/MCB.00725-12. Epub 2012 Oct 29.

10.

Regulation of the human prostacyclin receptor gene by the cholesterol-responsive SREBP1.

Turner EC, Kinsella BT.

J Lipid Res. 2012 Nov;53(11):2390-404. doi: 10.1194/jlr.M029314. Epub 2012 Sep 11. Erratum in: J Lipid Res. 2014 Nov;55(11):2444.

11.

Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders.

Qian H, Luo N, Chi Y.

J Aging Res. 2012;2012:121390. doi: 10.1155/2012/121390. Epub 2012 Feb 13.

12.

An eicosanoid-centric view of atherothrombotic risk factors.

Gleim S, Stitham J, Tang WH, Martin KA, Hwa J.

Cell Mol Life Sci. 2012 Oct;69(20):3361-80. doi: 10.1007/s00018-012-0982-9. Epub 2012 Apr 11. Review.

13.

Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation.

Wangorsch G, Butt E, Mark R, Hubertus K, Geiger J, Dandekar T, Dittrich M.

BMC Syst Biol. 2011 Oct 28;5:178. doi: 10.1186/1752-0509-5-178.

14.

Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century.

Patrignani P, Tacconelli S, Bruno A.

Front Pharmacol. 2010 May 6;1:2. doi: 10.3389/fphar.2010.00002. eCollection 2010. No abstract available.

15.

Prostacyclin receptor regulation--from transcription to trafficking.

Midgett C, Stitham J, Martin K, Hwa J.

Curr Mol Med. 2011 Oct;11(7):517-28. Review.

16.

Prostacyclin: an inflammatory paradox.

Stitham J, Midgett C, Martin KA, Hwa J.

Front Pharmacol. 2011 May 13;2:24. doi: 10.3389/fphar.2011.00024. eCollection 2011.

17.

Interaction of the human prostacyclin receptor with the PDZ adapter protein PDZK1: role in endothelial cell migration and angiogenesis.

Turner EC, Mulvaney EP, Reid HM, Kinsella BT.

Mol Biol Cell. 2011 Aug 1;22(15):2664-79. doi: 10.1091/mbc.E11-04-0374. Epub 2011 Jun 8.

18.

COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood.

Borgdorff P, Handoko ML, Wong YY, Tangelder GJ.

Open Cardiovasc Med J. 2010 Oct 21;4:198-205. doi: 10.2174/1874192401004010198.

19.

Endothelium-mediated control of vascular tone: COX-1 and COX-2 products.

Félétou M, Huang Y, Vanhoutte PM.

Br J Pharmacol. 2011 Oct;164(3):894-912. doi: 10.1111/j.1476-5381.2011.01276.x. Review.

20.

Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.

Warner TD, Nylander S, Whatling C.

Br J Clin Pharmacol. 2011 Oct;72(4):619-33. doi: 10.1111/j.1365-2125.2011.03943.x. Review.

Supplemental Content

Support Center